Dexcom (DXCM) Depreciation & Amortization (CF) (2010 - 2026)

Dexcom (DXCM) has reported Depreciation & Amortization (CF) for 17 consecutive years, with $68.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 8.25% year-over-year to $68.2 million in Q2 2026; TTM through Jun 2026 was $264.1 million, a 11.86% increase from a year earlier, with the FY2025 full-year figure at $251.8 million, up 15.66% from the prior year.
• Depreciation & Amortization (CF) was $68.2 million for Q2 2026 at Dexcom, up from $67.1 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $68.2 million in Q2 2026 and troughed at $36.3 million in Q4 2022.
• A 5-year average of $52.6 million and a median of $52.5 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) surged 85.53% in 2022 and climbed 0.23% in 2023, its largest moves.
• Over 5 years, Depreciation & Amortization (CF) stood at $36.3 million in 2022, then surged by 44.63% to $52.5 million in 2023, then increased by 10.1% to $57.8 million in 2024, then rose by 12.8% to $65.2 million in 2025, then rose by 4.6% to $68.2 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $68.2 million (Q2 2026), $67.1 million (Q1 2026), and $65.2 million (Q4 2025), per Business Quant data.